Michal Bassani-Sternberg
Tumor biology, Tumor immunology


Undergraduate, Technion - Israel Institute of Technology, Haifa, Israel

PhD, Max Planck Institute of Biochemistry, Germany and Technion - Israel Institute of Technology, Haifa, Israel

My work focuses on identifying clinically relevant cancer specific Human Leukocyte Antigen (HLA) ligands that will guide the development of personalized cancer immunotherapy using mass-spectrometry (MS), currently the only methodology to identify unbiasedly HLA binding peptides that are presented in vivo to cytotoxic T cells. In the clinic, we aim to integrate, for the first time, mass-spectrometry-based immunopeptidomics into the innovative translational clinical strategy of personalized immunotherapy within the department of oncology.

Ludwig Institute for Cancer Research, Lausanne
Agora Research Center
Rue du Bugnon 25A, CH-1005 Lausanne

T (41) 21 545 10 77
F (41) 21 692 59 95


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?